Improvement on binding of chondroitin sulfate derivatives to midkine by increasing hydrophobicity by Paz, José L. de & Nieto, Pedro M.
Journal Name  
COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1  
Please do not adjust margins 
Please do not adjust margins 
a. Glycosystems Laboratory, Instituto de Investigaciones Químicas (IIQ), cicCartuja, 
CSIC and Universidad de Sevilla, Americo Vespucio, 49, 41092 Sevilla, Spain. E-
mail: jlpaz@iiq.csic.es; pedro.nieto@iiq.csic.es 
Electronic Supplementary Information (ESI) available. See 
DOI: 10.1039/x0xx00000x 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
www.rsc.org/ 
Improvement on binding of chondroitin sulfate derivatives to 
midkine by increasing hydrophobicity  
J. L. de Paz*a and P. M. Nieto*a 
The interactions between chondroitin sulfate (CS) and a wide 
number of proteins modulate important biological processes. 
Here, the binding properties to midkine and pleiotrophin of 
sulfated, fully protected intermediates, typically obtained in the 
chemical synthesis of CS oligosaccharides, were tested for the first 
time. Using a fluorescence polarization competition experiment, 
we discovered that these synthetic precursors strongly bound 
these two closely related cytokines involved in cancer and 
inflammation. The relative binding affinities of these 
intermediates were significantly higher than those displayed by 
the corresponding fully deprotected oligosaccharides, indicating 
that the presence of hydrophobic protecting groups strongly 
enhanced the binding of CS-like derivatives to midkine. These 
compounds offer novel opportunities for the development of 
potent inhibitors/activators of CS-protein interactions with 
potential therapeutic applications. 
 Glycosaminoglycans (GAGs), a family of linear sulfated 
polysaccharides that includes heparin and chondroitin sulfate 
(CS), regulate a wide variety of biological processes through 
interactions with a large number of proteins.1-6 One of these 
proteins is midkine, a cytokine that plays an important role in 
the early central nervous system development and is involved 
in inflammation and cancer.7,8 Midkine is considered as a 
relevant molecular target for the treatment of various diseases 
and there is a great interest in the discovery of inhibitors that 
strongly bind to the protein, blocking its activity in the 
progression of pathological status, such as tumor invasion and 
rheumatoid arthritis.7,9 Midkine has two small independent 
domains formed by three beta sheets each and stabilized by 
disulfide bridges, linked by a long hinge region; its structure is 
completed with two unstructured segments at both ends of 
the sequence.7,8 It is known that midkine strongly binds to 
heparin and chondroitin sulfate chains and these molecular 
recognition events are essential for protein activity. It has also 
been demonstrated that the interaction between midkine and 
CS is mediated by specific oligosaccharide sequences, with a 
particular sulfation motif, the disulfated disaccharide GlcA-
GalNAc(4,6-di-OSO3), typical of CS-E subtype.10-12 
 The chemical synthesis of well-defined, CS 
oligosaccharides13-16 is a valuable tool to determine the 
structural requirements for CS-protein binding, paving the way 
for the design and development of CS mimetics17-20 that can 
act as more potent inhibitors/activators of those interactions. 
Typically, the preparation of these molecules involves the use 
of an orthogonal protecting group strategy that allows the 
selective introduction of sulfate groups at the desired 
positions to give protected intermediates such as 
tetrasaccharide 1 (Figure 1).21 This type of precursors are 
finally submitted to deprotection steps, liberating the hydroxyl 
and carboxyl groups and installing the 2-acetamido moiety 
present in natural CS sequences. For instance, basic hydrolysis 
followed by N-acetylation of compound 1 afforded the di-
benzylated derivative 2 that was finally hydrogenated to give 
the fully deprotected CS-E tetramer 3 (Figure 1).21 To the best 
of our knowledge, the activity of sulfated intermediates, such 
as 1, has never been tested. 
Figure 1. Structures of CS-E tetrasaccharide 3 and its synthetic 
precursors 1 and 2. Bz = benzoyl; Bn = benzyl; TFA = 
trifluoroacetyl; Lev = levulinoyl; MP = 4-methoxyphenyl. 
 
 Here, we have studied the interactions between midkine 
and 1 using a fluorescence polarization competition assay, 
previously developed by us.21-23 Briefly, the relative binding 
affinity of the sugar derivative was calculated by measuring its 
capacity to disrupt the formation of the complex between a 
 
COMMUNICATION Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
fluorescent heparin hexamer and midkine, which is 
characterized by a high polarization (P) value. Thus, we 
recorded the P of microplate wells that contained increasing 
concentrations of 1 in the presence of a fixed amount of 
midkine and fluorescent probe (Figure 2). The concentration 
dependent decrease of the P value showed that compound 1 
interacted with midkine. The curve was fitted to the equation 
for a one-site competitive interaction and an IC50 value of 1.3 
µM was obtained. Similar experiments were carried out to 
determine the IC50 values of 2 and 3 (Table 1 and supporting 
information, Figure S1). We unexpectedly found that the 
inhibitory potency increased from an IC50 value of 254 µM for 
deprotected tetrasaccharide 3 to a value of 31 µM for 2 and 
1.3 µM for 1, showing that the presence of hydrophobic 
protecting groups strongly increased the relative binding 
affinity of CS-like oligosaccharides for midkine. Interestingly, 
the IC50 value of 1, containing only four sulfate groups, is 
similar to the IC50 value of a heparin hexasaccharide with 13 
negative charges (1.1 µM).21 
Figure 2. Inhibition curve showing the ability of compound 1 to 
inhibit the interaction between midkine (63 nM) and 
fluorescent probe (10 nM). All the P values are the average of 
three replicate wells. 
 
Table 1. Inhibition of midkine/heparin interactions by 
synthetic oligosaccharides. 
 
Compound 1 2 3 4 5 6 7 
IC50 (µM) 1.3 31 254 15 17 20 >250 
 
 Fluorescence polarization technique analyses biomolecular 
interactions in solution. In order to validate our fluorescence 
polarization findings, we performed an alternative binding 
assay where we monitored the ability of compounds 1 and 3 to 
compete with a heparin-coated surface for midkine. We first 
attached a synthetic heparin hexasaccharide with an amine 
functionalized linker to Nunc Immobilizer Amino™ microtiter 
plates, following an experimental protocol previously 
developed by us.24 Thus, we created heparin-like coated wells 
that were incubated with mixtures containing midkine (23 nM) 
and tetrasaccharides 1 and 3 (Figure 3). We also included in 
this assay samples incubated with midkine alone, with no 
potential inhibitor, and with a mixture of midkine and dp18, an 
18-mer heparin oligosaccharide (from Iduron). The bound 
protein in each well was detected using a fluorescence 
microplate reader, after incubations with rabbit anti-midkine 
antibody and Alexa Fluor 488 labelled anti-rabbit secondary 
antibody. As shown in Figure 3, fluorescence intensities 
obtained at positions corresponding to compound 3 indicated 
that this molecule was not able to block the interaction 
between the heparin surface and midkine. On the contrary, we 
did not detect significant fluorescence signals for 1 and dp18, 
pointing out the inhibition of the heparin surface-midkine 
association. These data were in good agreement with our 
fluorescence polarization results, confirming that the affinity 
of protected 1 for midkine is higher than that corresponding to 
the fully deprotected tetramer 3. 
Figure 3. Competition assay employing heparin-functionalized 
microtiter plates. Heparin-coated wells were incubated with 
23 nM midkine alone or in the presence of dp18 (10 µM), 1 
and 3 (100 µM). For each sample, fluorescence signals are the 
average of six replicate wells and the error bars show the 
standard deviations for these measurements. 
 
 Next, we investigated if a similar trend can be also seen at 
the disaccharide stage. For this purpose, we carried out the 
fluorescence polarization competition experiment with 
derivative 4, a disulfated protected intermediate in the 
preparation of a CS-E disaccharide (Figure 4). A sigmoidal 
decrease in P with increasing disaccharide concentrations was 
again observed and an IC50 value of 15 µM was obtained (Table 
1 and Figure S2, supporting information). The competition 
assay was also performed with disaccharides 5 and 6 that were 
prepared as shown in Scheme S1 (see supporting information). 
Compound 5 was considered to assess the influence of 
substituting the glucuronic acid moiety by a glucose one on the 
binding affinities, while dimer 6 allowed studying the effect of 
replacing the cluster of sulfate groups from the reducing 
galactosamine to the non-reducing glucose unit. IC50 values in 
the range of 17-20 µM were obtained (Table 1 and Figure S2, 
supporting information). These results were in sharp contrast 
with that displayed by fully deprotected CS-E disaccharide 7,23 
which did not inhibit the fluorescent probe-midkine 
interaction (IC50 > 250 µM).21 Therefore, protected 
disaccharides 4-6 displayed equivalent relative affinities, much 
higher than that showed by the naturally occurring CS-E 
disaccharide. 
 
 
 
 
 
 
-2 -1 0 1 2
100
120
140
160
P
o
la
ri
z
a
ti
o
n
 (
m
P
)
log [inhibitor concentration (M)]
Compound 1
IC
50
 = 1.3 M
log IC
50
 = 0.12  0.06
R-square = 0.99   
0
20000
40000
60000
80000
100000
120000
140000
no
inhibitor
dp18 1 3
Fl
u
o
re
sc
e
n
ce
 In
te
n
si
ty
Journal Name  COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
Figure 4. Structures of disaccharides 4-7. Piv = pivaloyl. 
 
 Pleiotrophin is an extracellular heparin-binding protein that 
shows 45% amino acid sequence identity with midkine.25 Both 
growth factors form a two-member family of proteins that 
share many biological activities and strongly bind to 
oversulfated CS chains.26 We decided to investigate if the 
presence of hydrophobic protecting groups in 1 also increases 
the binding to pleiotrophin, compared with the fully 
deprotected tetrasaccharide. First, we measured the direct 
binding of the fluorescent probe to pleiotrophin, recording the 
P of microplate wells containing 10 nM concentration of probe 
and increasing concentrations of protein (Figure S3, supporting 
information). This initial experiment was required for the 
correct design of the competition assay. The binding curve was 
fitted to the equation for a one-site binding model and the 
dissociation constant (KD) of the interaction was calculated (KD 
= 125 nM). This value is slightly higher than the KD for the 
binding of probe to midkine21 and FGF-222 (44 and 117 nM, 
respectively). We then performed the inhibition assay with 
compounds 1-3 at 25 µM (Figure 5A). Disaccharide 7 and 5 kDa 
heparin dp18 were also included in this experiment as control 
samples, displaying, as expected, minimum and maximum 
activities, respectively. Protected tetramer 1 gave ~90% 
inhibition while 2 and 3 afforded much weaker activities. As in 
the case of midkine, we found that 1 was the most potent 
inhibitor of pleiotrophin, suggesting that the increased 
hydrophobicity of this molecule enhances its protein 
association. As shown in Figure 5B, the concentration-
dependent polarization curve for 1 afforded an IC50 value in 
the low micromolar range (5 µM). 
 The therapeutic applications of GAG oligosaccharides are 
seriously hampered by their promiscuous binding to many 
proteins. The discovery of compounds that selectively bind a 
limited number of GAG-binding proteins is highly interesting. 
For this reason, we also evaluated the interactions between 
compounds 1-3 and basic fibroblast growth factor (FGF-2) 
(Figure S4, supporting information). The IC50 values were 42, 
71 and 271 µM for 1, 2 and 3, respectively. Although 
tetrasaccharide 1 was again the most potent ligand, we 
observed only a ~6 fold inhibition increase for 1, as compared 
with the IC50 value of deprotected 3. Interestingly, in the case 
of midkine, the relative affinity of tetrasaccharide 1 was nearly 
200 times higher than that of compound 3. Our study indicates 
that compound 1 presents a certain degree of selectivity for 
midkine and pleiotrophin over FGF-2 (IC50 = 1.3-5 µM against 
42 µM). Structurally, both midkine and pleiotrophin contain 
two domains connected by a flexible linker,27-29 with 
hydrophobic amino acid clusters exposed on their surface. We 
hypothesized that this structural feature can explain the higher 
affinity of 1 for these two proteins. 
Figure 5. Interaction between pleiotrophin and compounds 1-
3, 7 and dp18. A) Competition assay at 25 µM concentration. 
The inhibition percentages were calculated by using the 
polarization of reference samples for 100 % and 0% inhibition 
(see supporting information). The displayed data are the 
average of two independent experiments, each one in three 
replicates. B) Inhibition curve showing the ability of compound 
1 to block the interaction between pleiotrophin (163 nM) and 
fluorescent probe (10 nM). All the P values are the average of 
three replicate wells. 
 
 In summary, we have discovered that synthetic sulfated 
intermediates from the preparation of CS oligosaccharides 
show a high affinity for midkine, and this binding is much 
stronger than that displayed by the fully deprotected 
sequences. Importantly, despite the multiple hydrophobic 
protecting groups, these derivatives present adequate 
solubility properties due to the presence of sulfate groups 
(compounds 1, 4, 5 and 6 are soluble in water at 100 µM 
concentration in the presence of 1% of DMSO). Compared with 
GAG polyanionic oligosaccharides, these derivatives have less 
charged groups, an interesting property for potential 
therapeutic applications.30 Besides the number and position of 
sulfate and carboxylate groups, our study indicates that 
hydrophobicity has also to be considered in the design of high-
affinity ligands for CS-binding proteins. In fact, several studies 
demonstrated that heparin mimetics with increased 
hydrophobicity exhibit interesting protein binding properties 
and biological activities.31-36 Sulfated, fully protected 
oligosaccharides, typically prepared during CS synthesis, offer 
an excellent scaffold to introduce chemical modifications and 
improve binding properties. Therefore, we consider that these 
compounds are good starting points for further development 
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of potent inhibitors/activators of CS-protein interactions and 
the subsequent modulation of important biological processes. 
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(FEDER) for financial support. 
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